Rexahn Pharmaceuticals, Inc.  

(Public, NYSEAMERICAN:RNN)   Watch this stock  
1.98
-0.03 (-1.49%)
After Hours: 1.96 -0.02 (-1.01%)
Oct 18, 5:44PM EDT  
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 1.97 - 2.09
52 week 0.38 - 7.10
Open 2.01
Vol / Avg. 0.00/479,515.00
Mkt cap 56.35M
P/E     -
Div/yield     -
EPS -1.03
Shares 31.72M
Beta -0.49
Inst. own 11%
Nov 6, 2017
Q3 2017 Rexahn Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 11, 2017
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 7, 2017
Q2 2017 Rexahn Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 15.94% -40.60%
Return on average equity 44.61% -51.95%
Employees 20 -
CDP Score - -

Address

15245 Shady Grove Rd Ste 455
ROCKVILLE, MD 20850-7203
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Officers and directors

Peter C. Brandt Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 45
Bio & Compensation  - Reuters
Ely Benaim Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 63
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 55
Bio & Compensation  - Reuters
Kwang Soo Cheong Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Richard J. Rodgers Independent Director
Age: 50
Bio & Compensation  - Reuters